The DOCK2 Knockout Ca Ski Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population created for targeted disruption of the human DOCK2 gene in the Ca Ski cervical carcinoma cell line. This loss-of-function model enables stable, constitutive elimination of DOCK2 protein expression, avoiding the limitations of transient RNA interference. The polyclonal nature ensures a heterogeneous pool of edited cells, reflecting a spectrum of CRISPR-induced disruptions without the bottleneck of clonal selection.
Ca Ski cells are a human cervical epidermoid carcinoma line established from a small intestine metastasis and stably harbor integrated HPV-16 genomes, making them a classic model for HPV-driven cervical carcinogenesis. Their epithelial morphology and tumorigenic capacity support studies of cancer cell proliferation, invasion, and interactions with the microenvironment. The cell line is widely used to investigate molecular mechanisms of oncogenesis and to evaluate therapeutic interventions.
DOCK2 functions as a guanine nucleotide exchange factor (GEF) that activates the small GTPases Rac1 and Rac2. Upon stimulation by chemokine receptors (e.g., CXCR4, CCR7) or the T-cell receptor, DOCK2 is recruited to the plasma membrane via its adaptor protein ELMO1. This localization drives Rac-mediated signaling, engaging downstream effectors such as p21-activated kinase 1 (PAK1), c-Jun N-terminal kinase (JNK), and p38 MAPK, which coordinate actin cytoskeletal remodeling through the ARP2/3 complex. Upstream, DOCK2 activity is regulated by phosphoinositide 3-kinase (PI3K) and Src family kinases, while Vav, CrkL, and talin-1 modulate its function.
In the Ca Ski cervical carcinoma model, DOCK2 knockout provides a platform to study its role in epithelial migration and tumor-immune interactions. Although best characterized in lymphocytes, DOCK2 expression has been reported in some epithelial cancers, and its contribution to chemokine-mediated actin reorganization in an HPV-16-positive background allows investigation of pathways that may impact cervical cancer progression and immune cell recruitment.
This polyclonal knockout product is suited for applications such as Western blotting, RT-qPCR, co-immunoprecipitation, chemotaxis assays, F-actin staining, and flow cytometry. Researchers can employ these cells to study lymphocyte migration and activation, model DOCK2-related immunodeficiency, explore chemokine signaling dynamics, and analyze immune cell infiltration in tumors. For additional information, please contact Ascent Research.
